Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Formycon AG manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active. These 2 pending office actions are handled by 2 distinct examiners but are located within 1 distinct art unit, suggesting a shared technical focus despite the involvement of different examiners. This situation often occurs when applications are closely related but assigned to different individuals within the same specialized group.
The busiest examiner is BUTTICE, AUDREY L, who is responsible for 1 busiest examiner pending office action. Since there are 2 pending office actions in total, the workload is split, with each of the 2 distinct examiners handling one action. This indicates a balanced distribution of the company's current prosecution tasks. For the legal team, this requires managing 2 separate examiner relationships within the 1 distinct art unit, which may allow for some consistency in the technical arguments presented to the patent office for the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| SANG, HONG | 1 | 55.0% | +62.4% |
| MOSS, NATALIE M | 1 | 30.8% | +17.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786423 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | SANG, HONG | 9d |
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | BUTTICE, AUDREY L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786423 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | SANG, HONG | 9d |
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | BUTTICE, AUDREY L | — |
| 17610894 | METHOD FOR REDUCING METHIONINE OXIDATION IN RECOMBINANT PROTEINS | MOSS, NATALIE M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | BUTTICE, AUDREY L | — | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 17786423 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | SANG, HONG | 1646 | §102§103§112Other | Final Rejection | 9d | Pending | Jun 16, 2022 |
| 17610894 | METHOD FOR REDUCING METHIONINE OXIDATION IN RECOMBINANT PROTEINS | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | — | Pending | Nov 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial